See more : Sime Darby Plantation Berhad (5285.KL) Income Statement Analysis – Financial Results
Complete financial analysis of Better Therapeutics, Inc. (BTTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Better Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Groupe JAJ (GJAJ.PA) Income Statement Analysis – Financial Results
- Assertio Holdings, Inc. (ASRT) Income Statement Analysis – Financial Results
- Pacific Ridge Exploration Ltd. (PEXZF) Income Statement Analysis – Financial Results
- Kings Entertainment Group Inc. (JKPTF) Income Statement Analysis – Financial Results
- Henkel AG & Co. KGaA (HEN3.SW) Income Statement Analysis – Financial Results
Better Therapeutics, Inc. (BTTX)
About Better Therapeutics, Inc.
Better Therapeutics, Inc. engages in developing software-based prescription digital therapeutics (PDT) platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions in the United States. Its lead product candidate in development is BT-001, an investigational PDT platform that uses digitally delivered Nutritional Cognitive Behavioral Therapy to treat type 2 diabetes. The company's products under development also include BT-002, a PDT that help patients with hypertension improve their blood pressure; and BT-003, a PDT that help patients with hyperlipidemia enhance cholesterol levels. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 8.00K | 18.00K |
| Cost of Revenue | 2.73M | 1.62M | 682.00K | 898.00K |
| Gross Profit | -2.73M | -1.62M | -674.00K | -880.00K |
| Gross Profit Ratio | 0.00% | 0.00% | -8,425.00% | -4,888.89% |
| Research & Development | 16.44M | 19.44M | 2.98M | 2.29M |
| General & Administrative | 14.84M | 8.79M | 2.46M | 2.20M |
| Selling & Marketing | 6.98M | 2.34M | 216.00K | 406.00K |
| SG&A | 21.82M | 11.12M | 2.67M | 2.60M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 38.26M | 30.56M | 5.65M | 4.89M |
| Cost & Expenses | 38.26M | 30.56M | 6.33M | 5.79M |
| Interest Income | 1.49K | 185.00 | 100.00 | 11.00 |
| Interest Expense | 1.49M | 185.00K | 100.00K | 11.00K |
| Depreciation & Amortization | 2.73M | 1.62M | 75.00K | 72.00K |
| EBITDA | -38.26M | -30.56M | -6.25M | -5.70M |
| EBITDA Ratio | 0.00% | 0.00% | -78,100.00% | -31,672.22% |
| Operating Income | -38.26M | -30.56M | -6.32M | -5.77M |
| Operating Income Ratio | 0.00% | 0.00% | -79,037.50% | -32,072.22% |
| Total Other Income/Expenses | -1.49M | -9.93M | 89.00K | -11.00K |
| Income Before Tax | -39.75M | -40.49M | -6.23M | -5.78M |
| Income Before Tax Ratio | 0.00% | 0.00% | -77,925.00% | -32,133.33% |
| Income Tax Expense | 7.00K | -153.00K | 153.00K | 11.00K |
| Net Income | -39.76M | -40.34M | -6.39M | -5.80M |
| Net Income Ratio | 0.00% | 0.00% | -79,837.50% | -32,194.44% |
| EPS | -1.69 | -1.71 | -0.85 | -0.25 |
| EPS Diluted | -1.69 | -1.71 | -0.85 | -0.25 |
| Weighted Avg Shares Out | 23.56M | 23.60M | 7.56M | 23.60M |
| Weighted Avg Shares Out (Dil) | 23.56M | 23.60M | 7.56M | 23.60M |
Better Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates
SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics to treat cardiometabolic diseases, today reported financial results for the second quarter 2023 and provided an update on progress towards achieving key corporate milestones....
Insiders are buying these two stocks in 2023
When company insiders — management, officers or any beneficial owners with more than 10% of a company's shares, as defined by the SEC — buy shares of their own company it's a bullish sign. That's because they believe the stock...
Better Therapeutics to Release Second Quarter 2023 Financial Results and Provide Business Update on August 09, 2023
SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics to treat cardiometabolic diseases, today announced it will release its second quarter 2023 financial results after the market closes on Wednesday, August 09, 2023....
Why Is Better Therapeutics (BTTX) Stock Up 39% Today?
Better Therapeutics (NASDAQ: BTTX ) stock is taking off on Tuesday as investors react to approval from the FDA for a Type 2 diabetes treatment. This covers AspyreRx, which is a prescription-only digital therapeutic treatment for patients 18 and older with...
Better Therapeutics Receives FDA Authorization for AspyreRx™ to Treat Adults with Type 2 Diabetes
SAN FRANCISCO--(BUSINESS WIRE)---- $BTTX #digitalhealth--Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing software to treat cardiometabolic diseases, today announced that the Food and Drug Administration (FDA) authorized AspyreRx™ (formerly BT-001), a prescription-only digital therapeutic (PDT) treatment indicated to provide...
Better Therapeutics, Inc. (BTTX) Q1 2023 Earnings Call Transcript
Better Therapeutics, Inc. (NASDAQ:BTTX ) Q1 2023 Earnings Conference Call May 11, 2023 8:30 AM ET Company Participants Mark Heinen - CFO Frank Karbe - President and CEO Diane Gomez - Chief Commercial Officer Mark Berman - Chief Medical Officer...
Better Therapeutics, Inc. (BTTX) Moves to Buy: Rationale Behind the Upgrade
Better Therapeutics, Inc. (BTTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Better Therapeutics, Inc. (BTTX) Q3 2022 - Earnings Call Transcript
Better Therapeutics, Inc. (NASDAQ:BTTX ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Mark Heinen - Chief Financial Officer Frank Karbe - President and Chief Executive Officer Mark Berman - Chief Medical Officer Diane Gómez-Thinnes...
Better Therapeutics, Inc. (BTTX) CEO Frank Karbe on Q2 2022 Results - Earnings Call Transcript
Better Therapeutics, Inc. (NASDAQ:BTTX ) Q2 2022 Earnings Conference Call August 11, 2022 8:30 AM ET Company Participants Mark Heinen – Chief Financial Officer Frank Karbe – President and Chief Executive Officer Mark Berman – Chief Medical Officer Conference Call...
Better Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
SAN FRANCISCO--(BUSINESS WIRE)--Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today reported financial results for the second quarter of 2022 and provided an...
Source: https://incomestatements.info
Category: Stock Reports